Fugl-Meyer Assessment (FMA)
Otherassessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
NCT Number: NCT04737018
In about 40 percent of cases, after a stroke, neuromotor impairment leads to activity limitations and the development of chronic functional disorders, which have a significant impact on patient autonomy.
In the early subacute phase, motor deficit in foot lifters is one of the factors limiting standing posture and ambulation, which is ultimately difficult to rehabilitate due to the lack of available techniques for obtaining early onset of useful active voluntary contraction.
The use of muscular focal vibration therapy, applied to relaxed muscle, may be of interest due to the portability and availability of the system and the neuromotor benefits demonstrated in healthy subjects and in acute and chronic post-stroke patients.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
evaluation of muscular strength score from 0 to 5
Assess functional walking and aerobic abilities
measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
score from 0 to 4 evaluation of spasticity
score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
Time frame: day 30
score from 0 to 34 Stroke-specific performance-based disability index that quantitatively assesses analytical motor skills in the lower limb.
Time frame: day 0, day 15, day 30 and month 2
score from 0 to 34 Stroke-specific performance-based disability index that quantitatively assesses analytical motor skills in the lower limb.
Time frame: day 0, day 15, day 30 and month 2
score of 0 (absence of contraction) to 5 (normal force)
Time frame: day 0, day 15, day 30 and month 2
measured with 2 Minute Walk Test
Time frame: day 0, day 15, day 30 and month 2
measures the patient's ability to maintain stable postures, as well as balance in changes of position score of 0 (cannot perform the activity) to 36 (can perform the activity)
Time frame: day 0, day 15, day 30 and month 2
with Winposturo platform
Time frame: day 0, day 15, day 30 and month 2
with Winposturo platform
Centre Hospitalier Universitaire de Saint Etienne
Other
Acronym: VIBRATAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details